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Abstract
Background: Atrial fibrillation (AF) patients with a high risk of stroke are recommended anticoagulation with warfarin. 
However, the benefit of warfarin is dependent upon time spent within the target therapeutic range (TTR) of their 
international normalised ratio (INR) (2.0 to 3.0). AF patients possess limited knowledge of their disease and warfarin 
treatment and this can impact on INR control. Education can improve patients' understanding of warfarin therapy and 
factors which affect INR control.
Methods/Design: Randomised controlled trial of an intensive educational intervention will consist of group sessions 
(between 2-8 patients) containing standardised information about the risks and benefits associated with OAC therapy, 
lifestyle interactions and the importance of monitoring and control of their International Normalised Ratio (INR). 
Information will be presented within an 'expert-patient' focussed DVD, revised educational booklet and patient 
worksheets. 200 warfarin-naïve patients who are eligible for warfarin will be randomised to either the intervention or 
usual care groups. All patients must have ECG-documented AF and be eligible for warfarin (according to the NICE AF 
guidelines). Exclusion criteria include: aged < 18 years old, contraindication(s) to warfarin, history of warfarin USE, 
valvular heart disease, cognitive impairment, are unable to speak/read English and disease likely to cause death within 
12 months. Primary endpoint is time spent in TTR. Secondary endpoints include measures of quality of life (AF-QoL-18), 
anxiety and depression (HADS), knowledge of AF and anticoagulation, beliefs about medication (BMQ) and illness 
representations (IPQ-R). Clinical outcomes, including bleeding, stroke and interruption to anticoagulation will be 
recorded. All outcome measures will be assessed at baseline and 1, 2, 6 and 12 months post-intervention.
Discussion: More data is needed on the clinical benefit of educational intervention with AF patients receiving warfarin.
Trial registration: ISRCTN93952605
Background
Atrial fibrillation (AF) is the most common arrhythmia in
clinical practice, for people aged 40 years and older the
lifetime risk of developing AF is approximately 25% [1].
AF is an independent risk factor for stroke, conferring a
five-fold excess risk in AF patients compared to those in
sinus rhythm [2] and accounts for almost 10-15% of all
ischaemic strokes and approximately one in four strokes
in those aged over 80 years [2]. Furthermore, when a
stroke occurs in association with AF, patients have sub-
stantially greater mortality, morbidity, disability and lon-
ger hospital stays [3].
Despite the overwhelming evidence that thrombopro-
phylaxis with warfarin substantially reduces the inci-
dence of stroke and mortality compared to placebo [4]
and is associated with a marked reduction in all strokes
when compared to aspirin [4], it remains under-utilised
[5]. Dose-adjusted warfarin does not confer a significant
increased risk of bleeding [6], however, poor anticoagula-
tion control, evidenced by a 10% rise in time out of INR
range (2.0 to 3.0), was significantly associated with an
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Page 2 of 6increased risk of death (OR, 1.29 [95% CI, 1.23 to 1.36]),
ischaemic stroke (OR, 1.10 [1.03 to 1.18]), and throm-
boembolic events (OR, 1.12 [1.06 to 1.19]) [7]. Recent
analyses have demonstrated that the minimum threshold
of time spent in the therapeutic INR range for warfarin to
be efficacious is ≥ 58%, although a TTR >65% is associ-
ated with a 2.29% (95% CI 1.57-3.35; p < 0.0001) reduc-
tion in stroke risk [8]. Analyses from an observational UK
cohort of AF patients [9] found that 51% of patients at
high risk of stroke (CHADS2 score ≥ 2) were outside the
therapeutic range for 50% or more of the time for the
duration of their warfarin treatment [9] and that TTR
needed to be >71% for warfarin to be efficacious [9].
Patients' illness representations and their beliefs about
their health are crucial determinants of whether antico-
agulant treatment, particularly with warfarin, is success-
ful [10-12]. Patients need to clearly understand the causes
and consequences of their AF, as well as the risks and
benefits of warfarin therapy, and incorporate this com-
plex medical information into their own belief system.
Studies suggest where patients have a greater knowledge
of warfarin therapy, INR values are more often within tar-
get range (p = 0.024) [13]. However, patients often exhibit
limited knowledge of their condition and their anticoagu-
lant therapy [13-16]. It is important that interventions
specifically target this group of patients to increase TTR
and maximise clinical outcomes with warfarin.
Behavioural and educational interventions that tar-
geted patients receiving oral anticoagulant (OAC) ther-
apy, the majority for AF (other indications included deep
vein thrombosis, prosthetic heart valves etc), found
reduced incidence of major bleeding and mortality and
increased TTR (e.g. Khan et al [17] found TTR 61.1%
prior to intervention vs. 70.4% post intervention; mean
difference 8.8; 95% CI: -0.2-17.8; p = 0.054), when com-
pared to usual care [17,18]. Our earlier pilot study exclu-
sively with AF patients [14] demonstrated a significant
improvement in the awareness of target therapeutic INR
(p < 0.0001) and factors which may affect INR levels (p =
0.005), with a trend towards improvement in the aware-
ness of the benefits of anticoagulants and bleeding risks,
six weeks after a brief educational intervention. Patients
need key information about their condition and treat-
ment to actively participate in their treatment manage-
ment.
Methods/Design
TREAT is a 'TRial of an Educational intervention on
patients' knowledge of Atrial fibrillation and anticoagu-
lant therapy, INR control, and outcome of Treatment
with warfarin'. It is a randomised controlled trial (RCT
[ISRCTN93952605]) of an educational intervention ver-
sus usual care in a population of AF patients that have
been newly prescribed anticoagulation treatment with
warfarin. The project is funded by an investigator-initi-
ated grant from Bayer Healthcare. The primary research
question will examine the effects of an intensive educa-
tional intervention on patients' International Normalised
Ratio (INR) control within the therapeutic range (INR 2.0
to 3.0) compared to patients receiving usual care. The
secondary endpoints will determine the effects of the
educational intervention on patients' knowledge of, and
perceptions of AF and their beliefs about anticoagulant
therapy. In addition, the relationship between INR con-
trol and the incidence of major and minor bleeding,
stroke and thromboembolic events compared to patients
receiving usual care will be explored.
To explore these endpoints TREAT will determine
whether there are differences between the intervention
group and the usual care group at baseline, 1, 2, 6 and 12
months post-intervention. Subgroup analysis of patient
groups (using age, gender and socio-demographic data)
will determine whether data outcomes relate to other fac-
tors such as the age or gender of the participants. Finally,
a health-care utilisation assessment will be undertaken to
determine the costs of the intensive educational interven-
tion compared to usual care. This will determine whether
the intervention would be cost effective if used on a larger
scale as part of standard 'usual care'.
Patients
AF patients newly referred for warfarin therapy, with
ECG-documented AF, will be eligible for inclusion.
Patients will be excluded from participation if they are
aged < 18 years old, have any contraindication to warfa-
rin, have previously received warfarin, have valvular heart
disease, are cognitively impaired, are unable to speak or
read English and have any disease likely to cause their
death within 12 months. Patients will be recruited from
the outpatient AF clinics at City Hospital, Sandwell Dis-
trict General Hospital (part of SWBH NHS Trust) and
Good Hope Hospital which collectively receive approxi-
mately 600 referrals for AF patients requiring anticoagu-
lant prophylaxis per annum (see figure 1. for CONSORT
recruitment flow diagram). Sandwell and West Birming-
ham NHS Trust serves a multi-ethnic inner-city popula-
tion of approximately 600,000 people, while Good Hope
Hospital serves North Birmingham, Sutton Coldfield, and
a large part of South-East Staffordshire, with a catchment
of 450,000.
Demographic and clinical information will be recorded
at baseline from the patient's hospital records. Individual-
ised annual risk of stroke will be determined based on
risk stratification proposed by the NICE guidelines (low/
moderate/high risk) [18] and the CHADS2 scheme [19].
Patients who are eligible for OAC therapy will receive a
standard explanation of the need for OAC therapy, and
the risks/benefits of such treatment. Those who are
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Figure 1 TREAT recruitment flow diagram
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Page 4 of 6accepting of anticoagulant therapy will be approached to
participate in this intervention study. Patients accepting
of warfarin therapy and who consent to participate will be
randomised to receive 'usual care' or the intensive inter-
vention.
Ethics approval for the TREAT study has been granted
by the Black Country Research Ethics Committee. All
participants will provide written informed consent.
Randomisation procedure
At the stage of randomisation the primary researcher will
check to ensure the patient meets the eligibility criteria
and does not meet any of the exclusion criteria. If the
patient is willing to take part consent, will be obtained
prior to randomisation. A computer generated list will
randomise patients in blocks of four and on an individual
basis with stratification by (a) age [< 70 and 70+]/sex and
(b) specialist AF clinic versus 'general' cardiology clinic.
There is one specialist AF clinic vs. two general cardiol-
ogy clinics involved in the trial. The specialist clinic is a
large clinic receiving AF referrals from the entire SWBH
Trust, therefore providing patient numbers equal to those
provided by the general cardiology clinics. Patients will
receive either 'usual care' (minimum of n = 78) or the
intensive educational intervention (minimum of n = 78),
in addition to 'usual care'. The randomisation schedule
was designed by an independent trials unit and the ran-
dom allocation will be obtained by the researcher tele-
phoning an associate researcher (who is not involved in
the data collection or data entry). The primary researcher
will be blinded to patient identification to ensure alloca-
tion concealment. A third researcher will match patient
identification numbers (generated by the primary
researcher) with randomisation codes (generated by the
associate researcher). Once the random allocation has
been obtained baseline data will be collected and an
intervention session will be arranged. Patients who refuse
to be randomised will be offered their respective hospi-
tals 'usual care' package.
Usual care
Patients randomised to usual care will be informed about
their condition and the need for anticoagulant therapy
only. All patients will also receive the standard informa-
tion booklet which contains basic lifestyle recommenda-
tions pertaining to OAC therapy. When patients are first
prescribed OAC, dosing officers and anticoagulation
nurses use an educational checklist to ensure they have
discussed all of the key information with the patients.
This information includes the purpose of their treatment,
future INR monitoring and factors which affect INR. This
yellow patient information booklet contains some basic
information pertaining to OAC therapy and their INR
record book.
Intensive education
Those in the intensive educational intervention arm will
attend one group session (between 2-8 patients) for one
hour, where they will be shown a DVD of information
about the need for warfarin, the risks and benefits associ-
ated with OAC therapy, potential interactions with food,
drugs, and alcohol, and the importance of monitoring,
and control of their INR. The information on the DVD
will be communicated in a variety of ways [i.e. by expert
patients, a cardiology consultant and examples of food/
alcohol dietary components with educational informa-
tion as a voiceover script].
The intervention session will be interactive, where the
patients will be encouraged to ask questions following
each 10 minute DVD section. Patients will also be asked
to complete a worksheet-based exercise which will serve
to reinforce the information presented. The chapters will
focus on AF and treatment recommendations, INR and
lifestyle recommendations and patient concerns about
OAC [including frequently asked questions answered by
the consultant cardiologist]. The content and format of
the information presented was finalised after consulta-
tion with a focus group of AF patients currently taking
OAC, and was based on the NICE guidelines for patients
[18] to ensure that it is suitable for a wide-range of
patients. In addition to the interactive group sessions,
patients will also be given the revised educational book-
let, which was originally developed for and employed in
our pilot study [14]. The complete intervention pack con-
tains a treatment diary whereby patients can self-monitor
the factors which affect the stability of their INR, an alert
card and their session worksheet. The content of the edu-
cational booklet will be covered in the group session and
will serve to reinforce the information and enable the
patient to refer to it in the future.
Study Outcomes
The primary endpoint is the proportion of time spent in
the therapeutic INR range, 2.0 to 3.0. All patients (inter-
vention and usual care groups) will attend the anticoagu-
lant outpatient clinic to have their INR checked using a
capillary blood sample. The frequency of the INR visits
will be at the discretion of the OAC clinic. The OAC
clinic staff will be blinded to the intervention arm the
patient is randomised to, to enable as 'naturalistic' as pos-
sible follow-up and monitoring). Every INR result from
baseline to the end of the study (12-months) will be
recorded. The proportion of time each patient spends in
the therapeutic INR range (2.0 to 3.0) will be calculated
by the method of linear interpolation [7] using data from
months 1 to 12 (to allow attainment of the correct dose of
warfarin during the first four weeks).
Secondary endpoints include (1) patients' knowledge
[an increase/decrease/or no change in knowledge will be
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about medication [20] (3) anxiety and depression [21] and
(4) illness representations ([22] see table 1). Ancillary
analyses will explore the relationship between INR con-
trol and incidence of minor and major bleeding, stroke,
thromboembolic events (given that the trial is not pow-
ered to detect these differences) and frequency of INR
checks. The number of strokes, bleeding and throm-
boembolic events will be determined from the computer-
ised clinical information system at the hospital. Patients
in both arms of the trial will receive the follow-up ques-
tionnaires by post 1, 2, 6 and 12 months after commenc-
ing OAC therapy. If returned questionnaires are not fully
completed, an independent researcher will contact the
patient by telephone to facilitate 100% completion of the
questionnaires.
Sample size
Power for the primary endpoint was calculated based on
data from a secondary analysis of the time within thera-
peutic range (TTR) from the ACTIVE-W cohort by Con-
nolly et al [8]. The power calculation assumes that usual
care patients would have mean TTR of 58% with a stan-
dard deviation [SD] of 7.5. We hypothesise a 6% improve-
ment in mean TTR in the intervention group (i.e. to 64%)
with a similar SD (i.e. 7.5). In order for this improvement
to be statistically significant with a 1-beta power of 0.99
and alpha = 0.01 we need a sample size of 154 subjects in
two equal groups of 77 each. However, to ensure confi-
dence and to allow for attrition, we intend to recruit in
excess of this figure.
For the secondary endpoint of improvement in knowl-
edge following the intervention, sample size was calcu-
lated based a study by Khan et al [17]. A sample size of
100 patients (allowing for a 20% attrition rate in comple-
tion of the questionnaires) will have at least 80% power to
detect an 18.5% increase in knowledge about the condi-
tion and factors affecting INR control between baseline
and follow-up.
Statistical analyses
All data will be analysed by intention to treat. All analyses
will be stratified by centre. Comparisons with the pri-
mary and secondary outcome measures will be made at
all time points to determine short and long term effects of
the intervention. For continuous variables (e.g., changes
in illness perception questionnaire or changes in time
spent within INR therapeutic range), the weighted mean
difference would be used. As the sample is randomised
we would not expect baseline differences between
groups.
Cost analysis
In addition to the cost of the intervention delivery (pro-
duction, staffing and resource costs) and anticoagulation
management, all patients will complete a questionnaire
(previously employed by Jowett et al [23]) to evaluate
their costs for two separate visits to the OAC clinic.
Patient costs incurred when travelling to the clinic,
including travel costs, other out of pocket expenses, loss
of leisure time and net wage deduction associated with
patients' clinic visits during working time will be col-
lected. Additional societal costs also include the value of a
companion's time.
Discussion
The TREAT trial seeks to recruit warfarin-naïve patients
from cardiology clinics who are recommended for and
accepting of OAC with warfarin. Providing an intensive
educational intervention will determine whether increas-
ing the information available to patients yields both clini-
cal benefit and cost effectiveness. This is a pragmatic
trial, thus limitations of the design are necessary for the
initial trial of the intervention. For example, patients are
not blinded to which arm of the trial they receive and
results will not be generalisable to patients with cognitive
impairment or limited English ability. However, if the trial
is successful the intervention will be available for carers of
patients with cognitive deficits and could potentially be
translated and piloted in a range of other languages.
Whilst the TREAT trial is powered for a surrogate out-
come marker, TTR, clinical outcomes will be observed.
TTR is an important outcome as INR control substan-
tially reduces the risk of adverse events. Thus the TREAT
study outcomes have implications for the management of
all patients receiving OAC, as the intervention aims to
improve knowledge on the key lifestyle factors which
affect INR control and medication adherence. If the
results are positive the educational intervention has
potential for online dissemination and the materials are
such that they can be delivered by a range of health-care
Table 1: Outcome measures for the TREAT study
Primary outcome 
measure
Secondary outcome measures
TTR of INR (analysed 
using methods 
defined by Connolly 
et al [8])
Patients' knowledge [14]
Beliefs about medication (BMQ, [20])
Illness representations (IPQ-B [22])
Cost effectiveness [23]
Hospital anxiety and depression [21]
Minor and major bleeding incidence 
Stroke incidence
Thromboembolic events
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Page 6 of 6professionals, with suitable training. The final results of
this study will not be available before late 2011.
Competing interests
The TREAT study is funded by an Investigator-Initiated Educational Grant from
Bayer Healthcare.
Authors' contributions
DES, GYHL, and DAL conceived the idea for the trial, DES and DAL drafted the
manuscript. HP, CBX and GYHL read and revised the manuscript. All authors
contributed to the development of the intervention.
Author Details
1University of Birmingham Centre for Cardiovascular Sciences, City Hospital, 
Dudley Road, Birmingham, B18 7QH, UK and 2School of Health and Life 
Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK
References
1. Lloyd-Jones DM, Wang TJ, Leip EP: Lifetime risk for developing atrial 
fibrillation: The Framingham Heart Study.  Circulation 2004, 
110:1042-1046.
2. Lip GYH, Edwards SJ: Stroke prevention with aspirin, warfarin and 
ximelagatran in patients with non-valvular atrial fibrillation: A 
systematic review and meta-analysis.  Thrombo Res 2006, 110:354-358.
3. Steger C, Pratter A, Martinek-Bregel M: Stroke patients with atrial 
fibrillation have a worse prognosis than patients without: data from 
the Austrian Stroke Registry.  Eur Heart J 2004, 25:1734-1740.
4. Hart RG, Pearce LA, Aguillar ML: Meta-analysis: antithrombotic therapy 
to prevent stroke in patients who have nonvalvular atrial fibrillation.  
Ann Intern Med 2007, 146:857-867.
5. Nieuwlaat R, Capucci A, Lip GYH: Antithrombotic treatment in real-life 
atrial fibrillation patients: a report from the Euro Heart Survey on Atrial 
Fibrillation.  Eur Heart J 2006, 27:3018-3026.
6. van Walraven C, Hart RG, Singer DE: Oral anticoagulants vs. aspirin in 
nonvalvular atrial fibrillation: an individual patient meta-analysis.  
JAMA 2002, 288:2441-2448.
7. Jones M, McEwan P, Morgan CL: Evaluation of the pattern of treatment, 
level of anticoagulation control, and outcome of treatment with 
warfarin in patients with non-valvar atrial fibrillation: a record linkage 
study in a large British population.  Heart 2005, 91:472-477.
8. Connolly SJ, Pogue J, Eikelboom J: Benefit of oral anticoagulation over 
antiplatlet therapy in atrial fibrillation depends upon the quality of the 
international normalised ratio achieved by centres and countries as 
measured by time in therapeutic range.  Cirulation 2008, 118:2029-2037.
9. Morgan CLI, McEwan P, Tukiendorf A: Warfarin tratment in patients with 
atrial fibrillation: observing outcomes associated with varying levels of 
INR control.  Thrombo Res 2009, 124:37-41.
10. Howitt A, Armstrong D: Implementing evidence based medicine in 
general practice: audit and quality of antithrombotic treatment for 
atrial fibrillation.  BMJ 1999, 318:1324-1327.
11. Protheroe J, Fahey T, Montgomery A: The impact of patients' preferences 
on the treatment of atrial fibrillation: an observational study of 
patients bases decision analysis.  BMJ 2000, 320:1380-1384.
12. Bungard TJ, Ghali WA, Teo KK: Why do patients with atrial fibrillation not 
recieve warfarin.  Arch of Intern Med 2000, 160:46-41.
13. Tang E, Lai C, Lee K: Relationships between patients' warfarin 
knowledge and anticoagulation control.  Ann Pharm 2003, 37:34-39.
14. Lane DA, Ponsford J, Shelley A: Patient knowledge and perceptions of 
atrial fibrillation and anticoagulant therapy: Effects of an educational 
intervention programme The West Birmingham Atrial Fibrillation 
Project.  Int J Cardiol 2006, 110:354-358.
15. Coelho-Dantas G, Thompson BV, Manson JA: Patients' perspectives on 
taking warfarin: qualitative study in family practice.  BMC Fam Pract 
2004, 5:15.
16. Nadar S, Begum N, Kaur B: Patients' understanding of anticoagulation 
therapy in multiethinic population.  J Royal Soc Med 2003, 96:175-179.
17. Khan TI, Kamali F, Kesteven P: The value of education and self-
monitoring in the management of warfarin therapy in older patients 
with unstable control of anticoagulation.  Br J Haematol 2004, 
126:557-564.
18. NICE: Atrial fibrillation: national clinical guideline for management in primary 
and secondary care Royal College of Physicians, London; 2006. 
19. Fuller R, Dudley N, Blacktop J: Avoidance hierarchies and preferences for 
anticoagulation--semi-qualitative analysis of older patients' views 
about stroke prevention and the use of warfarin.  Age Ageing 2004, 
33:608-611.
20. Horne R, Weinman J, Hankins M: The Beliefs about Medicines 
Questionnaire: The development and evaluation of a new method for 
assessing the cognitive representation of medication.  Psychol Health 
1999, 14:1-24.
21. Zigmond AS, Snaith RP: The hospital anxiety and depression scale.  Acta 
Psychiatrica Scandinavica 1983, 67:361-370.
22. Weinman J, Petrie KJ, Moss-Morris R: The illness perception 
questionairre: a new method for assessing the cognitive 
representation of illness.  Psychol Health 1996, 11:431-446.
23. Jowett S, Bryan S, Mahe I: A multinational investigation of time and 
travelling costs in attending anticoagulation clinics.  Value in Health 
2008, 11(2):207-212.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2261/10/21/prepub
doi: 10.1186/1471-2261-10-21
Cite this article as: Smith et al., TRial of an Educational intervention on 
patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR con-
trol, and outcome of Treatment with warfarin (TREAT) BMC Cardiovascular 
Disorders 2010, 10:21
Received: 14 December 2009 Accepted: 20 May 2010 
Published: 20 May 2010
This article is available from: http://www.biomedcentral.com/1471-2261/10/21© 2010 Smith et al; licensee BioMed Central Ltd. is an Open Access article distributed under th  terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC C rdiovascular Diso d rs 2010, 10:21
